no code implementations • 18 May 2022 • Isabel Chien, Nina Deliu, Richard E. Turner, Adrian Weller, Sofia S. Villar, Niki Kilbertus
While interest in the application of machine learning to improve healthcare has grown tremendously in recent years, a number of barriers prevent deployment in medical practice.
no code implementations • 8 May 2022 • Xijin Chen, Kim May Lee, Sofia S. Villar, David S. Robertson
In practice, it also affects their implementation where the simplest approach to overcome this is to continue to sample according to the original bandit algorithm, ignoring missing outcomes.
no code implementations • 15 Dec 2021 • Tong Li, Jacob Nogas, Haochen Song, Harsh Kumar, Audrey Durand, Anna Rafferty, Nina Deliu, Sofia S. Villar, Joseph J. Williams
TS-PostDiff takes a Bayesian approach to mixing TS and Uniform Random (UR): the probability a participant is assigned using UR allocation is the posterior probability that the difference between two arms is 'small' (below a certain threshold), allowing for more UR exploration when there is little or no reward to be gained.
no code implementations • 30 Oct 2021 • Nina Deliu, Joseph J. Williams, Sofia S. Villar
Increasing power in such small pilot experiments, without limiting the adaptive nature of the algorithm, can allow promising interventions to reach a larger experimental phase.
no code implementations • 22 Mar 2021 • Joseph Jay Williams, Jacob Nogas, Nina Deliu, Hammad Shaikh, Sofia S. Villar, Audrey Durand, Anna Rafferty
We therefore use our case study of the ubiquitous two-arm binary reward setting to empirically investigate the impact of using Thompson Sampling instead of uniform random assignment.
no code implementations • 13 Mar 2021 • Rob Johnson, Chris Jackson, Anne Presanis, Sofia S. Villar, Daniela De Angelis
Clinical trials of a vaccine during an epidemic face particular challenges, such as the pressure to identify an effective vaccine quickly to control the epidemic, and the effect that time-space-varying infection incidence has on the power of a trial.
no code implementations • ICML 2020 • Cong Shen, Zhiyang Wang, Sofia S. Villar, Mihaela van der Schaar
Phase I dose-finding trials are increasingly challenging as the relationship between efficacy and toxicity of new compounds (or combination of them) becomes more complex.